Relmada Therapeutics appoints Lotan to Chair of Clinical Advisory Board

Relmada Therapeutics (RLMD) announced the appointment of Yair Lotan, MD, a distinguished urologic oncologist, as Chair of Relmada’s Clinical Advisory Board. Dr. Lotan’s deep expertise in bladder cancer care and clinical research will be invaluable as Relmada prepares to initiate a Phase 3 trial for NDV-01 in H1 2026, building on positive Phase 2 data, presented at the American Urology Association 2025 Annual Meeting on April 28, 2025.